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Abstract
Background: About half of Americans 50 to 75 years old do not follow recommended colorectal cancer (CRC)
screening guidelines, leaving 40 million individuals unscreened. A simple blood test would increase screening
compliance, promoting early detection and better patient outcomes. The objective of this study is to demonstrate
the performance of an improved sensitivity blood-based Septin 9 (SEPT9) methylated DNA test for colorectal
cancer. Study variables include clinical stage, tumor location and histologic grade.
Methods: Plasma samples were collected from 50 untreated CRC patients at 3 institutions; 94 control samples
were collected at 4 US institutions; samples were collected from 300 colonoscopy patients at 1 US clinic prior to
endoscopy. SEPT9 methylated DNA concentration was tested in analytical specimens, plasma of known CRC cases,
healthy control subjects, and plasma collected from colonoscopy patients.
Results: The improved SEPT9 methylated DNA test was more sensitive than previously described methods; the test
had an overall sensitivity for CRC of 90% (95% CI, 77.4% to 96.3%) and specificity of 88% (95% CI, 79.6% to 93.7%),
detecting CRC in patients of all stages. For early stage cancer (I and II) the test was 87% (95% CI, 71.1% to 95.1%)
sensitive. The test identified CRC from all regions, including proximal colon (for example, the cecum) and had a
12% false-positive rate. In a small prospective study, the SEPT9 test detected 12% of adenomas with a false-positive
rate of 3%.
Conclusions: A sensitive blood-based CRC screening test using the SEPT9 biomarker specifically detects a majority
of CRCs of all stages and colorectal locations. The test could be offered to individuals of average risk for CRC who
are unwilling or unable to undergo colonscopy.
Background
It has been postulated that a screening test for colorectal
cancer (CRC) performed on blood that is collected in the
physician’s office would encourage more patients to
undergo screening, and could significantly decrease CRC
mortality. Increased screening would also likely result in
cost savings to the healthcare system, since more CRCs
would be detected at an earlier stage and newer, more
expensive chemotherapies could be avoided [1]. In 2008,
Lofton-Day et al. [2] described three blood-based molecu-
lar biomarkers for CRC that are shed from solid tumors
into the bloodstream [3-5]. The same group further devel-
oped an assay to detect one of the candidates, Septin 9
(SEPT9), which was differentially methylated in CRC tis-
sues [6] and can be sensitively and specifically detected in
blood plasma [7,8]. SEPT9 DNA methylation was analyzed
in several case-control studies, involving more than 3,000
subjects, which demonstrated an overall CRC detection
rate of 60 to 70% [7-9]. In 2010, the PRESEPT prospective
screening study of the SEPT9 biomarker was completed,
and the results were presented at the 2010 Digestive Dis-
ease Week (DDW) conference [10]. Nearly 8,000 asympto-
matic patients from 32 clinical sites in the United States
and Germany undergoing routine screening colonoscopy
participated in the study [10]. Blood was collected for each
subject, and the results of the SEPT9 test were compared
to colonoscopy with regard to CRC detection [10]. The
SEPT9 test detected 67% of CRCs and had a false-positive
rate of 11% [10], similar to results obtained in the previous
case-control studies.
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based CRC screening test with a significant increase in
sensitivity. Employing recent improvements for duplexing,
amplifying and detecting SEPT9 methylated DNA, we
demonstrate that the new test has dramatically improved
performance when compared to the PRESEPT study
method. In a case-control study, the new SEPT9 test is
demonstrated to specifically identify CRCs from blood
plasma with sensitivity similar to colonoscopy, exceeding
the rates published for stool-based tests and previously
described SEPT9 blood tests. The ability of the test to
detect cancers originating from all large intestine locations
is presented.
Methods
Human Plasma Samples
The clinical performance of the SEPT9 methylated DNA
assay was measured using blinded plasma specimens col-
lected from CRC patients and colonoscopy-verified control
subjects. Specimens were collected from 50 untreated
CRC patients prior to surgery at one US and two Russian
institutions between July 2008 and March 2009. The aver-
age age of the cancer patients was 62 (range: 42 to 85)
years. Control specimens were collected from 94 CRC-free
subjects at four institutions in the US within one year of
having a negative colonoscopy; collections occurred
between July 2008 and June 2010. Control subjects had an
average age of 58 (range: 40 to 86) years. A separate set of
controls involving 98 younger subjects between the ages of
18 to 49 was collected at ARUP Laboratories between Jan-
uary and April 2011. The average age in this group was 32.
For the small prospective study, blood specimens were
collected from 306 patients undergoing colonoscopy at a
single community clinic in the US from March to June
2011; 300 of the subjects were evaluable. The average
age of the cohort was 56 (range: 22 to 84) years; 195 of
these were 50 to 75 (average 59) years of age, were
asymptomatic, and underwent a routine screening
colonoscopy.
Written informed consent was obtained from all study
participants, adhering to local ethics guidelines.
Laboratory Methods
Analytical performance of the blood-based SEPT9 assay
Analytical performance of the assay was determined using
CpGenome wholly methylated human genomic DNA
(Chemicon/Millipore, Billerica, Massachusetts) added to
pooled normal human plasma (Innovative Research, Novi,
Michigan). The limit of detection of SEPT9 methylated
DNA at the specimen level was 6.25 pg/ml (at least one
out of the three reactions had SEPT9 detected 100% of the
time). The limit of detection at the PCR replicate level was
50 pg/ml (all three out of three reactions had SEPT9
detected 100% of the time). For the comparison study with
the PRESEPT Epi proColon PCR method, concentrations
ranging from 6.25 to 100 pg/ml of wholly methylated
human genomic DNA were used. DNA was extracted
from multiple aliquots of each concentration, treated with
bisulfite, and purified. Resultant DNA samples from each
concentration were pooled, so that the same DNA sub-
strate was used in the PCR method comparisons.
DNA Preparation and Bisulfite Conversion from Plasma
Specimens
For each subject, 10 ml of blood was collected in an EDTA
(ethylenediaminetetraacetic acid) vacutainer tube. Each
tube was centrifuged for 12 minutes at 1350 × g ± 150 × g
at room temperature. Plasma was transferred without dis-
turbing the buffy coat to a clean 15 ml conical tube. The
sample was centrifuged a second time for 12 minutes at
1350 × g ± 150 × g. Plasma was transferred without dis-
turbing the pellet to a 4 ml tube and stored at -70°C. Total
genomic DNA was extracted from 4 ml of plasma using a
nucleic acid extraction kit from Chemagen (Chemagic NA
Extraction kit catalog number 1045 distributed by Perki-
nElmer, Waltham, Massachusetts) following the product
insert protocol. Sample DNA was treated with bisulfite
conversion reagents prepared according to the protocol
from deVos et al. [8]. All bisulfite reagents were purchased
from Sigma-Aldrich (St. Louis, Missouri). After bisulfite
conversion, samples were purified using a bisulfite purifi-
cation kit from Chemagen (Chemagic Bisulfite Purification
Kit number 1036) following the product insert protocol.
DNA was eluted in 55 μL of elution buffer. If not used
immediately, eluted DNA was stored at -20°C for up to
one week.
Real-Time PCR
PCR amplification was performed in triplicate for each
sample using a modified version of the protocol from
deVos et al. [8]. Septin 9 (SEPT9) and beta-actin (ACTB)
control reactions were performed in the same reaction.
All primers and probes were synthesized by Integrated
DNA Technologies (Coralville, Iowa). Qiagen (German-
town, Maryland) 2X QuantiTect Multiplex Kit No ROX
was used. The total volume of the PCR was 25 μLu s i n g
10 μLD N Aa n d1 2 . 5μL 2X QuantiTect Kit. Sequences
and final concentrations were as follows: SEPT9-FWD
AAATAATCCCATCCAACTA (1.5 μM), SEPT9-REV
GATT-dSp-GTTGTTTATTAGTTATTATGT (1.5 μM),
SEPT9-Blocker GTTATTATGTTGGATTTTGTGGT-
TAATGTGTAG-SpC3 (1.0 μM), SEPT9-Probe FAM-
TTAACCGCGAAATCCGAC-BHQ_1 (0.075 μM),
ACTB-FWD GTGATGGAGGAGGTTTAGTAAGTT
(0.2 μM), ACTB-REV CCAATAAAACCTACTCCTCC
CTTAA (0.2 μM), ACTB-probe TEX615-ACCACCACC-
CAACACACAATAACAAACACA-IAbRQSp (0.075 μM).
Real-time PCR was performed on the LC480 thermal
cycler (Roche Applied Science, Indianapolis, Indiana)
using the following cycling conditions: activation at 95°C
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30 seconds, and final cooling to 40°C for 30 seconds. Heat-
ing rates were 4.4°C/second and cooling rates, 2.2°C/sec-
ond. Data were acquired at the end of each 56°C step.
Samples were analyzed using the AbsQuant/2
ndDerivative-
Max function of the LC480 software. For the comparison
study, the PCR method was performed as described in the
Epi proColon Instructions For Use pamphlet (Epigenomics
AG, Berlin, Germany). Analysis was done using the Abs-
Quant/Fit points function of the LC480 software following
the Epi proColon real-time PCR protocol.
PCR Data Analysis
In order to maximize sensitivity, SEPT9 was called positive
if at least one of the triplicate reactions had detectable
SEPT9. For plasma specimens that contain very low levels
of DNA, SEPT9 was ‘detected’ if the quantification cycle
(’crossing point’, CP) was less than 45 cycles, the highest
value reliably measured by the LC480 AbsQuant/2
ndDeri-
vativeMax analysis function. Plasma specimens were ‘not
detected’ if the SEPT9 CP was not measurable or was ≥
45.0 cycles and the ACTB CP was ≥ 36.0 cycles. If ACTB
was not detected, eluted DNA specimens were diluted
1:10 in water and re-run; for these studies, a CP of 39.0
cycles for ACTB was the maximum value accepted in
order to confirm a SEPT9 negative result.
Statistical Analysis
In the case control study, the sensitivity and specificity
of the SEPT9 test for detecting CRC were calculated as
follows:
Sensitivity = true positives/total cancers
Speciﬁcity = false positives/total controls
95% confidence intervals were calculated according to
the efficient-score method (corrected for continuity)
[11,12]. Negative and positive predictive values were cal-
culated as follows:
Negative predictive value (NPV) = true negatives/true negatives + false negatives
Positive predictive value (PPV) = true positives/true positives + false positives
For these NPV and PPV calculations, the prevalence
of CRC in the screening population was assumed to be
1 in 200 based on the work of Lieberman [13].
Results
Analytical performance of the improved blood-based
SEPT9 test
The SEPT9 test presented in this publication was speci-
fically developed to improve upon the method described
by deVos [8] that was used in the PRESEPT screening
study [10]. Each element of the deVos PCR detection
protocol was specifically optimized, followed by the
development of a robust duplex reaction whereby both
SEPT9 and ACTB (internal control) were measured in
the same reaction using different fluorescent tags, simi-
lar to the PRESEPT method. Both methods use essen-
tially the same reagents and can be completed in
roughly 24 hours, with approximately four hours of
hands-on time. The critical alterations compared to the
deVos and PRESEPT protocols are as follows: 1) SEPT9
PCR primer concentrations were increased; 2) ACTB
PCR primer concentrations were decreased; and 3) a dif-
ferent fluorescent label was used for the ACTB probe.
Figure 1 demonstrates the sensitivity of the improved
protocol compared to the PRESEPT method using
pooled human plasma spiked with various concentra-
tions of methylated human DNA. The increased sensi-
tivity of our method is exemplified by the 6.25 and 12.5
pg/ml dilutions, whereby the improved protocol
detected SEPT9 in an average of 40% of the replicates,
while the PRESEPT method was only capable of detect-
ing SEPT9 an average of 5% of the time. Further, the
detection of the SEPT9 signal occurred several cycles
earlier in the improved PCR method compared to the
PRESEPT protocol, demonstrating an increased sensitiv-
ity of at least ten-fold (Additional file 1, Supplementary
Table 1).
Clinical performance of the blood-based SEPT9 test
In a case-control study using specimens blinded to the
operator, the optimized SEPT9 test was able to identify
45 out of 50 cancers from the plasma of CRC patients,
with an overall sensitivity of 90% (95% confidence inter-
vals 77.4% to 96.3%). Three-quarters of the samples
were contributed by patients with early stage disease
(stages I and II), approximating the stage of disease typi-
cally detected during routine screening. The new SEPT9
t e s tw a sa b l et od e t e c t3 3o u to ft h e3 8o ft h e s ee a r l y
cancers for a sensitivity of 87%, and detected all late
stage cancers (stages III and IV). Additional file 2, Sup-
plementary Table 2 lists the subjects that participated in
the study, including demographic and clinical informa-
tion, together with SEPT9 and ACTB crossing points.
SEPT9 was ‘detected’ if the crossing point of at least one
out of three PCR replicates for each specimen had a
value of less than 45 cycles. Figure 2 is a diagram illus-
trating the overall performance of the SEPT9 test, with
each cancer stage shown individually. The SEPT9 test
detected CRCs arising from all regions of the colon and
rectum, including proximal tumors arising from the
cecum and ascending colon (Additional file 2, Supple-
mentary Table 2). Figure 3 illustrates the cancer detec-
tion frequency for each of the regions. The ten percent
of tumors that were not detected by the assay were
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methylation was detected in 11 out of 94 of the control
specimens collected from CRC-free colonoscopy-verified
individuals age 40 and older (Additional file 3, Supple-
mentary Table 3). The test had an overall specificity of
88%, consistent with previous reports [2,7-9]. This false-
positive rate of 12% was relatively stable across different
age cohorts from 50 to 75, with only a slight increase to
12.5% in the age 69 to 75 subset. In a separate study,
SEPT9 methylation was tested in 98 healthy younger
control subjects with no personal or family history of
CRC between the ages of 18 to 49; in this group, SEPT9
methylated DNA was detected in 6% of the subjects
(data not shown).
I no r d e rt og a u g ew h e t h e rt h ei m p r o v e dSEPT9 test
might be useful for detection of adenomas, blood was
collected from 306 colonoscopy patients at a community
c l i n i c ,n o n eo fw h o mw e r es h o w nb yc o l o n o s c o p yt o
have colorectal cancer. In the entire set of 300 evaluable
subjects (ages 24 to 83 years, average 56), only 12% of the
104 subjects with adenomas were detected using the
SEPT9 test (Table 1). The test was again shown to be
specific, with an overall false-positive rate of 3%. Simi-
larly, in the true screening population, those asympto-
matic individuals age 50 to 75 years (average 58), only
10% of individuals with adenomas were detected using
the blood test. Although the adenoma detection rate was
very low, more than half of the subjects in this study with
detectable SEPT9 were found by colonoscopy to possess
an adenoma or other polyp. The most common cause of
a false-positive result was diverticulosis, which accounted
for nearly half of the 3% false-positive rate.
Discussion
In several clinical studies, which together include over
10,000 subjects, SEPT9 has consistently demonstrated
utility for detecting CRC in the blood, with previous
publications citing a rate of 60% to 70% [2,7,8,10]. In
the PRESEPT prospective study of nearly 8,000 asymp-
tomatic individuals undergoing routine CRC screening,
the CRC detection rate was 67% with a specificity of
89%, similar to results obtained in case-control studies
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Figure 1 Comparison of the Improved SEPT9 PCR Detection Protocol with the PRESEPT Method using Analytical Specimens. Methylated
SEPT9 DNA was measured in pooled normal human plasma spiked with various concentrations of wholly methylated human DNA. Multiple
samples of each DNA concentration were prepared and pooled, allowing for the direct comparison of the PRESEPT and improved PCR detection
methods using identical DNA substrates. PCR, polymerase chain reaction.
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Page 4 of 9[10]. Our publication describes an improved SEPT9
blood test with enhanced sensitivity, proven by direct
comparison with the PRESEPT method using identical
analytical specimens. In a case-control study of 144
blinded specimens, the improved SEPT9 blood test
detected cancers of all stages and colorectal locations,
including 87% of early stage cases (stages I and II). The
new test exhibited an overall CRC detection rate of 90%
at 88% specificity, contrasting historical studies of
SEPT9.
The SEPT9 test is performed as a duplexed PCR, with
each reaction run in triplicate to maximize the amount
of DNA specimen analyzed. As was originally described
in previous SEPT9 methods, the improved test is cur-
rently configured to favor sensitivity over specificity,
whereby SEPT9 must be detectable in only one out of
three PCR replicates in order to call a positive test.
Assuming a CRC prevalence of 0.5% in the screening
population of individuals age 50 or older [13], and simi-
lar test performance in the screening setting as the case-
Overall                         95%  CI   
  Sensitivity  (45/50)    90.0%    (77.4%,  96.3%)
 Specificity  (83/94)    88.3%    (79.6%,  93.7%)
Early Stage (stage I, II)
 Sensitivity  (33/38)    86.8%    (71.1%,  95.1%)
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Figure 2 Sensitivity of the SEPT9 Blood-Based Test in Clinical Case-Control Study of 144 Subjects. Methylated SEPT9 DNA was measured
in plasma specimens donated by CRC patients and colonoscopy-confirmed control subjects. The percent of specimens with detectable
methylated SEPT9 DNA is illustrated by the solid bars. The test has been maximized for sensitivity by only requiring one out of three of the PCR
replicates to have methylated SEPT9 DNA detected. The specificity of the assay is 88% under these parameters. CRC, colorectal cancer; PCR
polymerase chain reaction.
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h a v ean e g a t i v ep r e d i c t i v ev a l u eo f9 9 . 9 4 %( T a b l e2 ) .A
more stringent variation of the test could be used to
maximize specificity to 100%, resulting in a positive
predictive value of 100%, however the sensitivity would
be reduced to 70%. While a 70% detection rate with
100% specificity might out-perform many of the other
laboratory-based screening tests for detecting CRC, it is
Figure 3 Location of Tumors Detected by SEPT9 Blood-Based Test. The diagram illustrates the locations of the primary tumors that were
detected using the blood-based methylated SEPT9 DNA test. Note that CRCs were identified throughout the large intestine, including proximal
regions such as the cecum. Three of the fifty blood specimens did not have tumor locations recorded, therefore these specimens are not
represented by this figure. CRC, colorectal cancer.
Table 1 SEPT9 detection in specimens collected prospectively from colonoscopy patients
All Evaluable
Subjects
(age 24-86 years)
Asymptomatic Subjects
(age 50-75 years)
Total SEPT9 + Total SEPT9 +
Total subjects 300 21 195 15
Colorectal cancer 0 0 0 0
Other cancer (carcinoid tumor) 1 0 0 0
Adenoma 104 12 78 8
Adenoma ≤ 10 mm 93 11 69 7
Adenoma > 10 mm 11 1 9 1
Hyperplastic/other polyp 38 1 27 1
Diverticulosis 43 4 27 3
Hemorrhoids 29 1 12 0
Crohn’s disease/colitis 7 0 3 0
Other colonic findings 21 0 9 0
Unsatisfactory prep/aborted 11 0 9 0
Normal 53 3 34 3
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detect a majority of cancers in their early stages would
provide a better screening option for the millions of
otherwise unscreened individuals.
Although tissue studies showed that adenomas have ele-
vated levels of methylated SEPT9 DNA comparable to
CRCs (data not shown), the adenoma detection rate in the
plasma was a modest 10% to 12%, consistent with previous
studies of the SEPT9 biomarker [7,10] and similar to that
reported for a standard guaiac fecal occult blood test
(FOBT) [13]. Note that these early FOBT tests, which
have been reported to detect lower percentages of colorec-
tal cancers [13], were shown in several large prospective
screening studies to provide a survival benefit to those
who underwent screening when compared to those who
did not [14-17]. There did not appear to be any specific
types or size of adenomas that were more amenable to
SEPT9 detection, although a more extensive study with
larger numbers of specimens will be required. These
results suggest that while the new method is very useful
for detecting a majority of CRCs of all stages and locations
from the plasma, a blood-based test for SEPT9 alone will
not be sufficient to detect mucosal precancerous lesions.
Methylated SEPT9 may normally play a role in
embryonic development in humans. In evaluating SEPT9
methylation in normal healthy young control subjects
under the age of 50 years, four women demonstrated
high concentrations of methylated SEPT9 DNA (Warren
et al., unpublished data). These women were subse-
quently found to be pregnant. Additional studies with
20 pregnant women showed that 100% of these subjects
had very high concentrations of methylated SEPT9 in
their plasma. Like other well-known cancer biomarkers
such as alpha-fetoprotein (AFP), carcinoembryonic anti-
gen (CEA) and CA-125, SEPT9 is implicated in both
embryogenesis and oncogenesis. Future studies are
planned to determine whether the sensitive SEPT9
blood test might be useful for therapeutic monitoring
and early detection of relapse, such as CEA and CA-125.
Conclusions
Although it is clear that CRC screening reduces mortality
by detecting the disease in its earliest stages when it is
most effectively treated [14-28], only one half of Ameri-
cans age 50 and older currently undergo any kind of
screening [29,30]. Patient compliance appears to be a
major hurdle [31]. Even those individuals who otherwise
adhere to screening recommendations for other cancers,
such as those who routinely undergo mammography, do
not faithfully follow colorectal screening guidelines [31].
Physician recommendation plays a significant role in
whether individuals are screened [32], however patient
preference appears to strongly determine what method, if
any, is ultimately used [33]. Reasons for not complying
with colonoscopy referral include the time-consuming
nature of the procedure and concern about invasiveness
[33]. Alternative methods for CRC screening such as
fecal testing have declined in recent years [32]. In addi-
tion to the challenges of patient compliance with stool
testing, such as the requirement for multiple samples and
the handling of specimens, the performance of these tests
is quite variable, with cancer detection rates ranging
from 30% to 85% (13). Newer stool based tests such as
the immunochemical FOBT (FIT), have demonstrated
sensitivity for adenoma detection [1]. While the SEPT9
methylated DNA test may perform comparably to colo-
noscopy in detecting CRCs, it lacks the advantage of
being potentially curative, and does not perform well for
adenoma detection. Nonetheless, we believe that a blood-
based CRC test, whereby specimens are collected in the
primary care setting every two or three years, will attract
a significant fraction of those individuals who are other-
wise non-compliant with recommended screening guide-
lines. Studies are underway to gain a better
understanding as to whether a blood-based test will
encourage individuals in the average risk screening popu-
lation to undergo testing of this type.
Additional material
Additional file 1: Supplementary Table 1. Comparison of improved
SEPT9 detection protocol with PRESEPT method using analytical
specimens.
Additional file 2: Supplementary Table 2. Measurement of SEPT9
methylated DNA in plasma of colorectal cancer patients.
Additional file 3: Supplementary Table 3. Control Plasma Specimens.
Abbreviations
ACTB: beta-actin gene; AFP: alpha-fetoprotein; avg: average; C: centrigrade;
CEA: carcinoembryonic antigen; CA-125: carbohydrate antigen 125; CI:
Table 2 Summary statistics for the SEPT9 test in colorectal cancer detection
Most Sensitive Moderate Sensitivity, Moderate Specificity Most Specific
Positive PCR replicates 1 out of 3 2 out of 3 3 out of 3
Sensitivity 90% 76% 70%
Specificity 88% 99% 100%
Positive predictive value 3.61% 26.30% 100%
Negative predictive value 99.94% 99.88% 99.85%
Warren et al. BMC Medicine 2011, 9:133
http://www.biomedcentral.com/1741-7015/9/133
Page 7 of 9confidence interval; CP: crossing point; CRC: colorectal cancer; DDW:
Digestive Disease Week; DNA: deoxyribonucleic acid; FIT: fecal
immunochemical test; FOBT: fecal occult test; g: gravity; GI: gastrointestinal:
pg: picogram; μl microliter; μM: micromolar; ml: milliter; NPV: negative
predictive value; PCR: polymerase chain reaction; PPV: positive predictive
value; SEPT9: septin 9 gene; US: United States.
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